Projects

Washington Vaccine Alliance - Home > Projects

WAVA members are currently actively working on the development of more than 15 different vaccines. With the successful acquisition of external funding, it is hoped that 2-3 of these projects will be ready for Phase I trials in the next 3 years.

Disease	Project Focus	Stage
Flu	Adjuvant formulation to increase dosage; Development of proteomic biomarker	Process engineering and early testing
HSV-2 (Herpes Simplex Virus type 2)	Adenovirus; DNA	Process engineering and early testing
Hepatitis C	Novel compounds	Antigen discovery
Hepatitis C	NK and T cells	Antigen discovery
Syphilis		Process engineering and early testing
E. coli O157	for cattle	Process engineering and early testing
HIV (Human Immunodeficiency Virus)	Novel candidates	Process engineering and early testing
Malaria	Human challenge (pre-erythrocytic antigen)	Process engineering and early testing
Malaria	Pregnancy	Process engineering and early testing
Malaria	Genetically attenuated parasites	Process engineering and early testing
Hepatitis B		Formulation/stabilization
DTP-HepB-Hib (Diptheria-HepatitisB-Haemophilus Influenzae Type b)		Formulation/stabilization
Rotavirus		Process engineering / manufacturing & epidemiology
Shigella		Process engineering / manufacturing & epidemiology
ETEC (Enterotoxigenic Escherichia coli)		Process engineering / manufacturing & epidemiology
Pneumococcus (Streptococcus pneumoniae)		Process engineering / manufacturing & epidemiology

Additional candidate immunogens within the WAVA members include Leishmania, Tuberculosis, Chlamydia, Salmonella, T pallidum, Delicobacter, Kaposi Sarcoma, Japanese Encephalitis, and Leprosy.